SXTC

China SXT Pharmaceuticals, Inc.

$2.88

-7.10%

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.

Source: Yahoo Finance
Q-Score28/ 100
Market Cap$298.3K
P/E—
Dividend Yield0.00%
52-Week Range—
Next Earnings—
Analysts—
Beta1.76
AI summary

Price & performance

1M-98.1%
3M-100.0%
YTD-100.0%
1Y-100.0%
52-week range—
Beta1.76
Full chart and returns against a benchmark

Q-Score

28/ 100

Quality against peers; 50 is the peer median.

Growth4
Risk4
Performance33
Valuation96
Profitability29
Leverage35
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2026

Revenue$1.1M
Net income-$6.2M
Net margin-545.2%
Historical fundamentals

Red flags in filings

2active red flags
Going-concern doubtJul 1, 2026
Material weakness in controlsJul 1, 2026
Filings, findings and the timeline

Revenue exposure

Largest customer87%
Regions, segments, customers and suppliers

Valuation

SXTCIndustryP/E—35.25P/S0.262.74EV/EBITDA—16.35P/B0.012.46PEG—0.87
Dividend yield0.00%
Every valuation metric